First steps toward the establishment of a German low-density lipoprotein-apheresis registry: Recommendations for the indication and for quality management

Therapeutic Apheresis

Volumn 6, Issue 5, 2002, Pages 381-383

  Schettler, V ^a   Wieland, E ^a   Armstrong, V W ^a   Kleinoeder, T ^a   Grunewald, R W ^a   Muller G A ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Apheresis registry; Hypercholesterolemia; Indication for low density lipoprotein apheresis; Low density lipoprotein apheresis

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

APHERESIS; CHOLESTEROL BLOOD LEVEL; EXTRACORPOREAL CIRCULATION; FAMILIAL HYPERCHOLESTEROLEMIA; GERMANY; HOMOZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REGISTER; REVIEW; TREATMENT INDICATION;

CHOLESTEROL, LDL; CONSENSUS DEVELOPMENT CONFERENCES; CORONARY DISEASE; GERMANY; HUMANS; PRACTICE GUIDELINES; PROGRAM DEVELOPMENT; REGISTRIES;

EID: 0036796663     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2002.00426.x     Document Type: Review

References (13)

1. Bundesvereinigung K. Beschliisse des Bundesausschusses der A≠rzte und Krankenkassen. Dt A≠rztebl 1998;95:A-1930.
2. Keller C. LDL-apheresis: results of longterm treatment and vascular outcome. Atherosclerosis 1991;86:1-8.
3. Stegmayr B. Is there a place for LDL-apheresis in nonhomozygous patients? Int J Artif Organs 1999;22:723-5.
4. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, Grutzmacher P, Keller C, Kettner U, Kleophas W, Ko≠ster W, Olbricht CJ, Richter WO, Seidel D, and the HELP-Study Group. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest 1994;24:724-32.
5. Conti CR. Evolution of NCEP guidelines: ATPI-ATPIII risk estimation for coronary heart disease in 2002. National Cholesterol Education Program. Clin Cardiol 2002;25:89-90.
6. Assmann G, Schulte H, Cullen P. New and classical risk factors - the Munster heart study (PROCAM). Eur J Med Res 1997;2:237-42.
7. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002;89:50C-7C.
8. No author. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600.
9. Malchesky PS, Koo AP, Rybicki LA. Apheresis technologies and clinical applications: the 2000 International Apheresis Registry. Ther Apher 2001;5:193-206.
10. Norda R, Stegmayr BG. Swedish Apheresis Study Group Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study group. Transfus Apheresis Sci 2001;24:49-55.
11. Korach JM, Guillevin L, Petitpas D, Berger P, Chillet P. Apheresis registry in France: indications, techniques, and complications. French Registry Study Group. Ther Apher 2000;4:207-10.
12. Ilhan O, Uskent N, Arslan O, Arat M, Ozkalemkas F, Ozturk G, Kalayoglu SB, Ozet A, Tombuloglu M, Arpaci F, Ovali E, Anak S. National survey of hemapheresis practice in Turkey (1998). Transfits Sci 2000;22:195-201.
13. Rock GA, Tricklebank GW, Kasaboski CA. Plasma exchange in Canada. The Canadian Apheresis Study Group. CMAJ 1990:142:557-62.